about
Therapeutic interventions for symptomatic treatment in Huntington's diseaseTherapeutic interventions for disease progression in Huntington's diseaseDopamine agonist therapy in early Parkinson's diseaseTherapeutic interventions for sleep disorders in Parkinson's diseaseTherapeutic interventions for daytime somnolence in Parkinson's diseasePiribedil for levodopa-induced complications in Parkinson's diseasePiribedil for symptomatic management of Parkinson's diseasePiribedil versus levodopa in early Parkinson's diseaseTherapeutic interventions for symptomatic treatment in Huntington's diseaseTherapeutic interventions for disease progression in Huntington's diseasePhenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyDysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark).Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease.Pharmacotherapy in Parkinson's disease: case studies.The management of patients with early Parkinson's disease.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review.Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.An evidence-based approach in the treatment of Huntington's disease.Associated movement disorders in orthostatic tremor.Late-stage Parkinson disease.Branded versus generic clopidogrel in cardiovascular diseases: a systematic review.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies.Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.Current and future therapeutic strategies for Parkinson's disease.Skin cancers and precancerous lesions in Parkinson's disease patients.Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.Putaminal petechial haemorrhage as the cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated with MRI findings.Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers.Quality and reporting of guidelines on the diagnosis and management of dystonia.GIGYF2 mutations are not a frequent cause of familial Parkinson's disease.Psychosocial impact of Parkinson's disease-associated dysarthria: Cross-cultural adaptation and validation of the Dysarthria Impact Profile into European Portuguese.Usefulness of OSLER test in Parkinson's disease.Comments on: 'Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial'.
P50
Q24239893-3C13A44A-7D4E-449F-B272-BB1048E97D8EQ24239973-11F5AF2F-74CC-490D-9802-D3CBBE14ACC2Q24243105-5F01A62B-4E2A-4BBE-9EB0-363CC40B11C1Q24243257-EBF99281-55C3-4FAC-8373-7555570B28C0Q24243418-38B2A0D6-1F75-4E15-9889-759A2B9D4482Q24244549-4D6F7D44-6E40-4CA2-818A-60BB73CA52E3Q24244952-A2E8FE0E-0E62-4793-B5DC-E554C9CF1DCFQ24244961-61662394-9BB5-4A33-A579-7A5C9530C346Q24245803-CB5AD0C1-012A-41AB-AC79-EBE16603F22BQ24245948-D31C2E84-E600-41DC-9E45-F32C56FA289FQ29614953-28668437-A339-4C03-8383-25E4705D644DQ30368449-0946669A-6012-485E-BA38-F1E1C8D0759EQ33371185-2300BC20-850E-43E0-8E47-8D834C2BF545Q34021853-6FB0DB37-4716-4ED7-9C62-3040E1104E60Q34049272-18629262-E51D-4790-A70D-1D47CCE87F0FQ34409459-E1F06DDE-EEA4-468C-B635-D0732E89FF0DQ34826166-66DA0940-8943-4BD3-8285-ABD551F0DB40Q37098986-79333856-539A-476B-86C8-468427EC358EQ37640903-46DCC80F-CE92-4827-BFF3-F28A2AF4DD63Q37798777-B83C06D9-E61B-4A5B-B26F-5779FA62C2AAQ37969340-74E77BF6-D403-40DE-94FC-B3D6D4549C3EQ38009299-F67B143F-4A3C-4895-92AC-ED72DC0C3E87Q38024984-7C4EE583-1CA5-4676-B68B-580E1F67FE04Q38063135-0FCE1DDC-56C2-4989-AE61-18C158AA9061Q38070888-1977F734-6471-4C8C-A9C8-49DC03052043Q38134700-D9584465-D79E-4973-AE95-0E06F54058EDQ39350609-43B76A73-0160-4717-BD9D-CE505C27CC50Q39947425-5065D2EE-1CD3-4856-9E96-47CEEF733191Q40211306-5C766318-F1DD-48E0-B8AF-331702FDCA6CQ42675021-DF8B8618-00E7-41DC-B183-601147504781Q42766008-14BFFF44-1278-479D-80F6-FEDA15B5D25CQ42837237-B703F4C2-C684-4A3E-8AC6-75AF78C448EEQ43709645-DF182DBD-C436-4C6E-AB1C-42EF8D3108EAQ44361036-B3B7A3D7-E31D-4D3D-BEDB-5D62141FB682Q44825538-B442685E-F13A-4CFD-97FC-17BCACC9A853Q47238149-4948B486-754E-4DAA-97EA-CDB72A60E54FQ47688721-313A74AB-576E-4680-93FD-617145E7C05CQ48160541-FD18FCAE-948F-4E3A-8992-2EBED65A0EF0Q48217506-DEC85549-BF0C-4D1E-A14B-CD8C1D82FD57Q48357585-F726EBA6-CC26-417B-8255-96CCFAB7976E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joaquim Ferreira
@ast
Joaquim Ferreira
@en
Joaquim Ferreira
@es
Joaquim Ferreira
@nl
Joaquim Ferreira
@sl
type
label
Joaquim Ferreira
@ast
Joaquim Ferreira
@en
Joaquim Ferreira
@es
Joaquim Ferreira
@nl
Joaquim Ferreira
@sl
altLabel
Ferreira JJ
@en
Joaquim J Ferreira
@en
prefLabel
Joaquim Ferreira
@ast
Joaquim Ferreira
@en
Joaquim Ferreira
@es
Joaquim Ferreira
@nl
Joaquim Ferreira
@sl
P106
P1153
7403252466
P21
P31
P4012
P496
0000-0003-3950-5113